Notifications

Home

Stocks
- Stock Screener
- Market Movers
- Insider Trades
- Upcoming Earnings
- Upcoming Dividends
Options
- Unusual Options Activity
- Implied Volatility Rank
- Volatility %Change
News
Upcoming IPOs

Guardant Health Inc (GH)

$63.43 +1.55 (2.50%)

Overview
Financial
Short Interest
Institutional Holdings
Dividends
Charts

Market Cap	7.66B
Revenue (ttm)	739.02M
Net Income (ttm)	-436.37M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-59.05%
Debt to Equity Ratio	-3.65

Volume	1,525,800
Avg Vol	2,500,590
Day's Range	N/A - N/A
Shares Out	124.71M
Stochastic %K	99%
Beta	1.43
Analysts	Strong Sell
Price Target	$59.65

Company Profile

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company provides precision oncology testing services comprising Guardant360, a panel of genetic tests; Guardant360 LDT that measures 730+ genes and supports all guideline-recommended biomarkers; Guardant360 CDx Test, a liquid biopsy test; Guardant360 Response Test, a blood-only liquid biopsy; Guardant360 TissueNext Test, a tissue-based test with AI-pow...

Industry: Diagnostics & Research

Sector: Healthcare

Phone: 855 698 8887

Fax: 888 974 4258

Website: guardanthealth.com

Address:

3100 Hanover Street, Palo Alto, United States

WAJeff Aug. 27 at 1:49 PM

$GH More sold at 64.50, 64.70 52 week high

0 · Reply

NeverFadeTheOracle Aug. 27 at 8:53 AM

$GH

0 · Reply

WAJeff Aug. 26 at 9:03 PM

$GH $63.48 52 week high

0 · Reply

Gator5326 Aug. 26 at 7:41 PM

$GH not far enough, not fast enough! No stopping this train!

0 · Reply

healthcareguru Aug. 26 at 2:27 PM

$GH too far, too fast…time to come back in, esp considering new/faster competition in MRD from $EXAS. Looking for $55. 👎

0 · Reply

parcha Aug. 25 at 2:09 AM

Source: TipRanks Financial $SHOP $COIN $PD $GH https://share.google/eeLAxzKc8KfGBPcCA

0 · Reply

Lisboa63 Aug. 22 at 6:56 PM

$GH next stop is 73

0 · Reply

WAJeff Aug. 22 at 6:41 PM

$GH Pondering where to add more of this, 20 day is all the way back at $50.23. Not sure I’ll have a chance there.

0 · Reply

G101SPM Aug. 22 at 2:56 PM

$GH $62.36 bid. SELL/TAKE PROFIT on 10% on net position. DAC $16.49. EXIT $65.00 (Legacy Holding status)

0 · Reply

BillHwangsRevenge Aug. 21 at 7:05 PM

$GH outperforming $GRAL Which is why I recommend buying a basket of themed stocks and not going all in on just one.

1 · Reply

Guardant Health to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

Aug 15, 2025, 5:05 PM EDT - 11 days ago

Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aug 7, 2025, 9:45 PM EDT - 19 days ago

Baron Capital's Top Health Care Stock Picks And Misses From Q2 2025

ACLX BSX EW EXAS ISRG LLY MASI

Aug 4, 2025, 8:06 AM EDT - 23 days ago

American Cancer Society and Guardant Health Partner to Expand Cancer Screening Access and Advance Health Equity

Jul 31, 2025, 4:05 PM EDT - 26 days ago

Guardant Health to Participate in the Canaccord Genuity 45th Annual Growth Conference

Jul 31, 2025, 2:10 PM EDT - 26 days ago

Guardant Health Analysts Increase Their Forecasts After Stronger-Than-Expected Q2 Earnings

Jul 31, 2025, 11:13 AM EDT - 27 days ago

Guardant Health, Inc. (GH) Q2 2025 Earnings Call Transcript

Jul 30, 2025, 4:05 PM EDT - 27 days ago

Guardant Health Reports Second Quarter 2025 Financial Results and Increases 2025 Revenue Guidance

Jul 30, 2025, 8:09 AM EDT - 4 weeks ago

Guardant Health and James Van Der Beek Team Up to Raise Awareness About New Advances in Colorectal Cancer Screening for Adults 45+

Jul 29, 2025, 8:07 AM EDT - 4 weeks ago

New RADIOHEAD Study Validates Use of Guardant Reveal Tissue-Free Monitoring for Earlier Detection of Immunotherapy Response in Advanced Cancer

Jul 15, 2025, 11:01 AM EDT - 6 weeks ago

First Patient Enrolled in National Cancer Institute's Vanguard Study Evaluating Guardant Health's Shield Multi-Cancer Detection Test

Jul 14, 2025, 8:00 AM EDT - 6 weeks ago

Guardant Health to Report Second Quarter 2025 Financial Results on July 30, 2025

Jun 10, 2025, 7:05 AM EDT - 2 months ago

Guardant Health Wins Fast Company's 2025 World Changing Ideas Award for Shield Blood Test for Colorectal Cancer Screening

Jun 9, 2025, 8:05 AM EDT - 2 months ago

New Study Published in ESMO Open Highlights Guardant Reveal's Performance in Detecting Minimal Residual Disease in Patients with Early-Stage Breast Cancer

Jun 3, 2025, 2:56 PM EDT - 3 months ago

Why Is Cancer Diagnostic Guardant Health Stock Trading Higher On Tuesday?

Jun 3, 2025, 8:05 AM EDT - 3 months ago

FDA Grants Breakthrough Device Designation to Guardant Health's Shield Multi-Cancer Detection (MCD) Test

Jun 2, 2025, 8:05 AM EDT - 3 months ago

National Comprehensive Cancer Network (NCCN) Updates Colorectal Cancer Screening Guidelines to Include Shield Blood-Based Screening

Jun 2, 2025, 7:00 AM EDT - 3 months ago

SERENA-6 Phase III Trial Demonstrates Clinical Value of Guardant360 CDx Test to Detect Emergence of Endocrine Resistance and Inform a Switch in Therapy Before Radiological Disease Progression in Advanced Breast Cancer

May 31, 2025, 8:05 AM EDT - 3 months ago

In Largest Molecular Residual Disease (MRD) Study in Colon Cancer, Guardant Reveal Testing Prior to Chemotherapy Provides Robust Stratification for Risk of Disease Recurrence and Survival to Enable Timely Treatment Decisions

May 27, 2025, 5:30 PM EDT - 3 months ago

Guardant Health Introduces Nearly a Dozen Groundbreaking Smart Liquid Biopsy Applications for Guardant360 Liquid Test

May 22, 2025, 5:05 PM EDT - 3 months ago

Guardant Health and Collaborators to Present Over 19 Studies Demonstrating Role of Liquid Biopsy in Advancing Precision Oncology at 2025 ASCO Annual Meeting

May 21, 2025, 8:05 AM EDT - 3 months ago

Guardant Health Introduces Comprehensive Immunohistochemistry Testing for Solid Tumors

May 20, 2025, 8:05 AM EDT - 3 months ago

Guardant Health Introduces Hereditary Cancer Testing to Identify Inherited Predispositions to Certain Types of Cancer

May 8, 2025, 4:05 PM EDT - 3 months ago

Guardant Health to Participate in Upcoming Investor Conferences

May 8, 2025, 9:20 AM EDT - 3 months ago

TIME Names Guardant Health Co-CEOs to 2025 TIME100 Health List of the 100 Most Influential People in Global Health This Year

May 1, 2025, 4:33 PM EDT - 4 months ago

Guardant Health: Tailwinds Are Beginning To Impact The Financials

Apr 30, 2025, 10:25 PM EDT - 4 months ago

Guardant Health, Inc. (GH) Q1 2025 Earnings Call Transcript

Apr 30, 2025, 4:05 PM EDT - 4 months ago

Guardant Health Reports First Quarter 2025 Financial Results and Increases 2025 Revenue Guidance

Apr 29, 2025, 4:20 PM EDT - 4 months ago

Guardant Health Presents Data Demonstrating Strong Performance of Shield Multi-Cancer Detection Test Across 10 Tumor Types

Apr 28, 2025, 9:12 AM EDT - 4 months ago

CORRECTING and REPLACING Guardant Health Launches Guardant360 Tissue, First Tissue Molecular Profiling Test with Comprehensive Multiomic Analysis to Provide a More Complete View of Cancer

Apr 28, 2025, 8:05 AM EDT - 4 months ago

Guardant Health Launches Guardant360 Tissue, First Tissue Molecular Profiling Test with Comprehensive Multiomic Analysis to Provide a More Complete View of Cancer

Apr 24, 2025, 8:05 AM EDT - 4 months ago

Guardant Health Announces Strategic Collaboration With Pfizer to Support Development and Commercialization of New Cancer Therapies Using Guardant Infinity Smart Liquid Biopsy Platform

PFE

Apr 22, 2025, 8:05 AM EDT - 4 months ago

Guardant Health to Present Data Highlighting Advances in Multi-Cancer Detection and Liquid and Tissue Molecular Profiling at AACR

Apr 10, 2025, 4:05 PM EDT - 4 months ago

Guardant Health to Report First Quarter 2025 Financial Results on April 30, 2025

Apr 3, 2025, 8:05 AM EDT - 5 months ago

Guardant Health and Bayshore HealthCare Partner to Expand Access to Advanced Precision Oncology Testing in Canada

Mar 25, 2025, 4:05 PM EDT - 5 months ago

Guardant Health's Shield Blood Test Now Covered for VA Community Care Beneficiaries

Mar 13, 2025, 7:51 AM EDT - 5 months ago

Guardant Health: Great Buy On Dips For Strong Diagnostics Verticals Despite Premium Valuation

Mar 11, 2025, 2:48 PM EDT - 6 months ago

Medicare To Reimburse Guardant Health's Shield Colorectal Cancer Test, Analyst Expects $10M In Revenue

Mar 11, 2025, 7:00 AM EDT - 6 months ago

Guardant Health Receives ADLT Status From CMS for Shield Blood Test

Feb 27, 2025, 8:05 AM EST - 6 months ago

New Guardant Health/Harris Poll Survey Highlights Patient Fear and Anxiety as Major Barriers to Colorectal Cancer Screening, but Blood Test Option Offers Hope for Change

Feb 21, 2025, 1:33 PM EST - 6 months ago

What's Going On With Cancer Diagnostic Firm Guardant Health On Friday?

Feb 20, 2025, 11:14 PM EST - 6 months ago

Guardant Health, Inc. (GH) Q4 2024 Earnings Call Transcript

Feb 20, 2025, 4:05 PM EST - 6 months ago

Guardant Health Reports Fourth Quarter and Full Year 2024 Financial Results and Provides 2025 Outlook

Feb 13, 2025, 9:45 AM EST - 6 months ago

Guardant Health: Asymptomatic Screening Creating An Asymmetric Opportunity

Feb 7, 2025, 6:30 AM EST - 7 months ago

Guardant Health Announces Debt Exchange Transactions

Jan 30, 2025, 4:05 PM EST - 7 months ago

Guardant Health to Report Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025

Jan 30, 2025, 8:05 AM EST - 7 months ago

Guardant Health's Shield Test Selected by Abu Dhabi Department of Health for Blood-Based Colorectal Cancer Screening Program

Jan 23, 2025, 8:05 AM EST - 7 months ago

Guardant Health to Present Data at ASCO GI Demonstrating the Value of Its Precision Oncology Tools for Cancer Detection, Treatment Decisions and Therapy Development

Jan 21, 2025, 2:15 PM EST - 7 months ago

Guardant Health Gains Medicare Coverage For Colorectal Cancer Monitoring Test

Jan 21, 2025, 8:05 AM EST - 7 months ago

Guardant Health Receives Medicare Coverage for Guardant Reveal™ on Smart Liquid Biopsy™ Platform for Surveillance Testing in Colorectal Cancer Patients

WAJeff Aug. 27 at 1:49 PM

$GH More sold at 64.50, 64.70 52 week high

0 · Reply

NeverFadeTheOracle Aug. 27 at 8:53 AM

$GH

0 · Reply

WAJeff Aug. 26 at 9:03 PM

$GH $63.48 52 week high

0 · Reply

Gator5326 Aug. 26 at 7:41 PM

$GH not far enough, not fast enough! No stopping this train!

0 · Reply

healthcareguru Aug. 26 at 2:27 PM

$GH too far, too fast…time to come back in, esp considering new/faster competition in MRD from $EXAS. Looking for $55. 👎

0 · Reply

parcha Aug. 25 at 2:09 AM

Source: TipRanks Financial $SHOP $COIN $PD $GH https://share.google/eeLAxzKc8KfGBPcCA

0 · Reply

Lisboa63 Aug. 22 at 6:56 PM

$GH next stop is 73

0 · Reply

WAJeff Aug. 22 at 6:41 PM

$GH Pondering where to add more of this, 20 day is all the way back at $50.23. Not sure I’ll have a chance there.

0 · Reply

G101SPM Aug. 22 at 2:56 PM

$GH $62.36 bid. SELL/TAKE PROFIT on 10% on net position. DAC $16.49. EXIT $65.00 (Legacy Holding status)

0 · Reply

BillHwangsRevenge Aug. 21 at 7:05 PM

$GH outperforming $GRAL Which is why I recommend buying a basket of themed stocks and not going all in on just one.

1 · Reply

ProtectThisHouse Aug. 21 at 6:50 PM

$GH Bullish long term but I’m completely out after taking profits. Switched to puts. I think it’s due for a correction. Also a bit worried about the possibility of dilution. If I were them, I would do it here. They have profitability issues and are hitting 52 week highs.

4 · Reply

Monkey_Banana_Genius Aug. 21 at 5:09 PM

$GH 💪

0 · Reply

WAJeff Aug. 21 at 4:18 PM

$GH $62.08 52 week high

0 · Reply

aaxaa Aug. 21 at 3:39 PM

$GH continuation underway

0 · Reply

Markus01 Aug. 21 at 2:38 PM

Market Leader Stream $BZ: 23.75 (+1.67) | $LIF: 86.65 (+1.48) | $PRIM: 111.97 (+1.39) | $CECO: 46.49 (+1.28) | $GH: 59.74 (+1.24)

0 · Reply

CanadaPride Aug. 15 at 4:59 PM

$GH $ASTH come and have a look at $AGL balance sheet. Look at yearly revenues appeox 6B..market sitting close to 500M. Cashbonnhand is 300M and debt close to 50M.

1 · Reply